Search
Alectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalAlectinib is a second generation oral drug that selectively inhibits the activity of anaplastic lymphoma kinase (ALK) tyrosine kinase. It is specifically used in the treatment of non-small cell lung cancer (NSCLC) expressing the ALK-EML4...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesMaropitant
go.drugbank.com/drugs/DB11427ExperimentalVet approvedMaropitant, used as maropitant citrate, is a neurokinin receptor antagonist, which was developed by Zoetis specifically for the treatment of motion sickness and vomiting in dogs. It was approved by the FDA in 2007 for use in dogs, and mo...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesGrazoprevir
go.drugbank.com/drugs/DB11575ApprovedGrazoprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that i...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesAsunaprevir
go.drugbank.com/drugs/DB11586ApprovedWithdrawnAsunaprevir, also named BMS-650032, is a potent hepatitis C virus (HCV) NS3 protease inhibitor. It has been shown to have a very high efficacy in dual-combination regimens with daclatasvir in patients chronically infected with HCV genoty...
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesVelpatasvir
go.drugbank.com/drugs/DB11613ApprovedInvestigationalVelpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsIsavuconazole
go.drugbank.com/drugs/DB11633ApprovedInvestigationalIsavuconazole is an triazole antifungal with broad spectrum of activity and good safety profile . It is approved by the FDA and EMA for the treatment of invasive aspergillosis and mucormycosis. It works by inhibiting fungal cell membrane...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP2B6 InducersArtenimol
go.drugbank.com/drugs/DB11638ApprovedInvestigationalArtenimol is an artemisinin derivative and antimalarial agent used in the treatment of uncomplicated Plasmodium falciparum infections [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2011 in com...
Categories: Cytochrome P-450 CYP2C19 Inhibitors, Cytochrome P-450 CYP2D6 InhibitorsVinflunine
go.drugbank.com/drugs/DB11641ApprovedInvestigationalVinflunine is a third-generation member of the vinca alkaloid family with anti-tumour actions. It was first described in 1998 at the Pierre Fabre research center in France. Like other vinca agents, vinflunine is an anti-mitotic agent tha...
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesPitolisant
go.drugbank.com/drugs/DB11642ApprovedInvestigationalPitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessiv...
Categories: Cytochrome P-450 CYP1A2 Inducers, Cytochrome P-450 CYP2B6 InducersPacritinib
go.drugbank.com/drugs/DB11697ApprovedInvestigationalMyelofibrosis (MF) is a rare disorder characterized by hematopoietic abnormalities and fibrosis within the bone marrow. The underlying cause of primary MF is unknown, but secondary MF can arise in patients with a history of polycythemia ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 Inducers